Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Sees Revenues Slide, Losses Mount in Q2

NEW YORK, July 26-Revenues dwindled and losses mounted for Luminex in the second quarter of 2002, the company reported yesterday.

 

Revenues for the quarter ended June 30, 2002 were $3.2 million, down from $4.7 million in the second quarter of the previous year.

 

Losses increased to $6.1 million for the quarter ($0.21 per share) from $4.4 million or $0.15 per share in the equivalent quarter last year.

 

The company held $41 million in cash and short-term investments at the end of June, down from $51 million at the end of the 2001 calendar year.

 

Luminex chair and CEO Mark Chandler said in a statement that the company's revenues increased from the first quarter of the year, and pointed to a steep hike in royalties.

 

For more information, see the press release.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.